Breast Cancer Trials
-
MERCK KEYLYNK MK7339-009
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)
Available at 3 locations
-
USO 18282
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) In Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens (IMMU-132-09)
Available at 1 location
-
USO 17026
A Phase II, Multicenter, Open-Label, Three-Cohort, Noncomparative Study To Assess The Efficacy And Safety Of Alpelisib Plus Fulvestrant Or Letrozole In Patients With PIK3CA Mutant,Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (Abc), Who Have Progressed On Or After Prior Treatments (CBYL719X2402)
Available at 1 location
-
USO 19009
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Available at 3 locations
-
USO 18232
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)
Available at 1 location
-
USO 17188
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Available at 5 locations
-
Alliance A011502 (ABC Trial)
A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer
Available at 6 locations